Tumor-associated macrophage-derived exosome miR-194 confers cisplatin resistance in GC cells.

ABSTRACT:

Objective

At all stages of gastric cancer (GC), cisplatin is the first-line chemotherapeutic agent, but its efficacy remains limited, with a response rate of less than 20%, largely because of resistance to the drug. It aims to determine whether macrophage-derived exosomes are involved in the mechanism of cisplatin resistance, in order to identify potential methods for reversing resistance and improving patient outcomes.

Methods

Macrophages induced by IL-13 and IL-4 were characterized using flow cytometry, then co-cultured with GC cells and cisplatin. Cell viability and apoptosis were subsequently evaluated through CCK-8 assays and flow cytometry. Exosome miR-194, derived from M2 macrophages, was characterized and co-cultured with gastric cancer cells and cisplatin to assess

SUBMITTER: Zhou Y 

PROVIDER: S-EPMC11792191 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature